Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety
O Schmidt, HAM Kerstjens, E Bleecker, E Meltzer, T Casale, E Pizzichini, M Engel, LJ Bour, CB Verkleij, PM Moroni-Zentgraf, ED Bateman · Pneumologie · 2014 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Asthma is not controlled in some patients, despite using medium-dose ICS. Methods: Two identical Phase III, randomised, double-blind, double-dummy, placebo (pbo)-controlled, parallel-group trials (NCT01172808/821) assessed tiotropium (tio) efficacy/safety. Patients with symptomatic asthma and pre-bronchodilator FEV1 60 – 90% predicted, using medium-dose ICS (400 – 800 µg budesonide equivalent), were randomised to once-daily tio 5 µg or 2.5 µg (via Respimat® Soft Mist™ Inhaler), salmeterol (sal, active comparator without inferential analysis) or pbo. Other LABAs were not permitted. Pre-specified co-pr…
